as 11-21-2024 4:00pm EST
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.
Founded: | 2019 | Country: | United States |
Employees: | N/A | City: | RADNOR |
Market Cap: | 590.3M | IPO Year: | 2023 |
Target Price: | $30.00 | AVG Volume (30 days): | 255.3K |
Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -3.33 | EPS Growth: | N/A |
52 Week Low/High: | $6.06 - $16.91 | Next Earning Date: | 11-11-2024 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Rodman David Malcom | MLYS | Chief Medical Officer | Nov 11 '24 | Sell | $15.00 | 5,026 | $75,398.04 | 140,991 | |
Rodman David Malcom | MLYS | Chief Medical Officer | Nov 6 '24 | Sell | $15.03 | 25,482 | $383,065.81 | 140,991 | |
Congleton Jon | MLYS | Chief Executive Officer | Oct 11 '24 | Sell | $13.52 | 15,271 | $206,433.38 | 895,941 | |
Levy Adam Scott | MLYS | CFO and Secretary | Oct 11 '24 | Sell | $13.57 | 10,757 | $146,003.69 | 236,854 |
MLYS Breaking Stock News: Dive into MLYS Ticker-Specific Updates for Smart Investing
TipRanks
9 days ago
Thomson Reuters StreetEvents
10 days ago
MT Newswires
10 days ago
GlobeNewswire
10 days ago
GlobeNewswire
16 days ago
GlobeNewswire
17 days ago
GlobeNewswire
23 days ago
GlobeNewswire
a month ago
The information presented on this page, "MLYS Mineralys Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.